Adverse event monitoring in oncology clinical trials

Author： Russell Jeffery S   Colevas A Dimitrios  

Publisher： Future Science

ISSN： 2041-6792

Source： Clinical Investigation, Vol.3, Iss.12, 2013-12, pp. : 1157-1165

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The importance of monitoring adverse events in statin, and other, clinical trials

By Golomb Beatrice Alexandra  

Clinical Investigation, Vol. 3, Iss. 10, 2013-10 ,pp. : 913-916

Future Science

Access to resources Recommend Favorite

Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections

By Khashab Mohammed M.   Xiang Jim   Kahn James B.  

Current Medical Research and Opinion, Vol. 22, Iss. 10, 2006-10 ,pp. : 1997-2006

Informa Healthcare

Access to resources Recommend Favorite

Pathology is a necessary and informative tool in oncology clinical trials

By  

THE JOURNAL OF PATHOLOGY, Vol. 232, Iss. 2, 2014-01 ,pp. : 185-189

John Wiley & Sons Inc

Access to resources Recommend Favorite

Lessons for the monitoring of safety in clinical trials

By  

EUROPEAN JOURNAL OF HEART FAILURE, Vol. 20, Iss. 1, 2018-01 ,pp. : 148-148

John Wiley & Sons Inc

Access to resources Recommend Favorite

Data Monitoring Committees in adaptive clinical trials

By Lin Min   Chow Shein-Chung  

Clinical Investigation, Vol. 3, Iss. 7, 2013-07 ,pp. : 605-607

Future Science

Access to resources Recommend Favorite